

# Most Innovative Oncology Entrepreneur 2022: Frank Gansauge



**LDG Laboratories, a research and treatment provisions firm led by Dr Gansauge, is a front runner in dendritic cell therapies for tumours. Targeting the malignant growths by taking samples of progenitor cells in the blood and working with them in a lab setting, it has become a pioneer of one of the least invasive and procedurally aggressive cancer treatments currently available. Headed up by experts in their fields who have each contributed massively to modern science, the efforts of LDG Laboratories have thrust it onto the main stage of cancer therapy development as a field.**

LDG Laboratories – or the Laboratories of Dr Gansauge – is a German company that helps its patients to fight cancer by boosting their immune system. Working by way of dendritic cell therapy, the effectiveness of such procedures in targeting skin, kidney, breast, pancreas, and prostate cancer has been proven time and time again; it has also been shown that patients suffering from colon and ovarian cancer benefit from the treatment. Fundamentally, this treatment was developed thanks to the work of the ‘father of modern immunotherapy’, Professor Ralph Steinmann, who was honoured with the Nobel Peace Prize for Medicine in 2011, the highest honour a scientist can receive.

After this, countless research and therapy facilities have been turning towards dendritic cell therapy as cancer treatment solutions, increasing accessibility and being the inspiration behind 7,000 scientific papers looking into the impacts, benefits, and results of such treatments of various cancerous bodies. Thanks to the increased research and development that Professor Steinmann made possible, dendritic cell therapy is already legal in a few select countries such as the USA. Critically, as a direct part of this movement, LDG became the exemplary research laboratory that it is today when it took over Cabion Technologies, retaining the original

team in order to preserve the excellence they had already achieved.

Now, LDG Laboratories proudly looks back on over 500 successfully performed therapies in partnership with LANEX-DC. This exemplary team takes great pride in helping everyone it can in any way possible in this manner. With so many different cancers that afflict the human body, it is pivotal that modern medicine can keep up with developments, findings, and technological growth so that treatments can keep getting better and better, aiding patients to find growths of mutating cells quickly so they can treat it early. This, above all, is the most critical factor when it comes to cancer treatment.

Dendritic cell treatment, therefore, can be used in the treatment of all manner of different cancers – but nominally skin, kidney, breast, pancreas, and prostate – in order to help the body’s own immune system in treating the disease. Using a special procedure, it targets progenitor cells that have the potential to become dendritic cells, isolating them from the blood and promoting this behaviour using certain messenger substances, exposing cells to such substances in lab settings before re-introducing them.

By cultivating them outside of the body, LDG Laboratories has discovered a way to



handle all potentially confounding variables in order to make the process more reliable. Furthermore, its process is as stress-free as it can possibly make it, with only a small 200 ml sample of blood needed from a patient. From there, the isolation of the dendritic progenitor cells can begin under stable, temperature neutral conditions, processed in clean rooms certified to EU GMP guidelines, allowing the researchers in question to keep a close eye on the proceedings in order to keep it safe and efficient.

Nominally, therapy by use of dendritic cells has become known as a gentle therapy. In contrast to procedures such as chemotherapy or radiation, in which foreign substances or radiation are used to fight the tumour, treatment by way of dendritic cells uses the body’s own immune system



to fight the cancer. It bolsters the body’s ability to fight back against harmful growths, and although side effects can occur, these have been reported universally to be far less profound than that of more aggressive treatment options.

All of this has been made possible by Professor Doctor Frank Gansauge, a specialist in surgical oncology, chemotherapy, and subsequent therapies. A father, dedicated medical professional, student, and professor, he completed his medical studies in Tübingen and Cardiff, gaining notoriety as a front-runner in modern scientific advances related to cancer and cancer treatment. From 1992 to 1999, the Professor – a native of Sindelfingen originally – worked as an assistant doctor in a Surgical capacity at Ulm University Hospital.

Using this experience as a springboard, he found his passion truly lay in finding new and better ways to help people struggling with tumours that would be just as good at reducing the growths as aggressive treatments without the added trauma of such therapies. He also has experience with heading up day clinics and research laboratories, working in the surgical clinic proper as a senior physician for two years, where he expanded on his already expansive knowledge of surgical oncology within chemotherapy and its follow-ups.

In 1995, Professor Gansauge received the Fred Stephans Award, and the Merckle Research Award some four years on, publishing over 160 scientific journals and writing numerous book chapters during this

time. Additionally, he has also become a reviewer for renowned scientific journals and a co-editor of Langenbeck’s Archives of Surgery, contributing to modern science in exemplary ways that have propelled LDG Laboratories and his own research into prominence. Hoping to continue to promote the effectiveness of and improve the processes within dendritic cell tumour therapies in the future, he hopes that he and his team will be able to provide this treatment for countless more individuals in the coming year. Working with diligence, tenacity, and respect, LDG Laboratories only hopes to help treat malignant tumours for all patients who require its help.

Company: LDG Laboratories Dr Gansauge  
Contact: Frank Gansauge  
Website: labor-gansauge.de